Tirzepatide Weight Loss for MRD+ Early Breast Cancer

NCT06517212 on ClinicalTrials.gov · last registry update 2026-02-12

A small phase 2 — 48 participants, against a typical 110. Due to report 31 August 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: ctDNA efficacy. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Baylor Research Institute
Sponsor type: Other
Enrollment: 48
Started: 2024-11-26
Primary completion: 2029-08-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

ctDNA efficacy

Conditions studied

Breast Cancer · Breast Neoplasms · Breast Cancers

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.